DIDO1

Across TCGA pan-cancer cohorts, DIDO1 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated DIDO1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher DIDO1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DIDO1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

KICH, SCLC, and HNSC are the cancer types where DIDO1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
SCLC	DFS	Median	II,III,IV	0.082	0.564	.002	30	view →
HNSC	OS	Median	All	0.270	0.720	<.001	24	view →
UCEC	DFS	Median	II,III,IV	0.851	0.300	.016	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
STAD	OS	Median	III,IV	0.917	0.360	.023	8	view →
KIRP	DFS	Median	All	0.178	0.867	<.001	6	view →
LUSC	DFS	Median	All	0.168	0.515	.013	4	view →
ESCA	DFS	Median	II,III,IV	0.256	0.532	.011	3	view →
LIHC	DFS	Median	II,III,IV	0.861	0.411	.040	1	view →
SKCM	OS	Median	All	0.226	0.337	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

DIDO1–KICH (DFS)

Open the KICH breakdown →